Martin Dow Marker products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Pharmaceutical manufacturer - Martin Dow Group · Karachi · Pakistan
Martin Dow Group pharmaceutical entity manufacturing and marketing medicines in Pakistan with a long-standing industrial presence.
Martin Dow Marker products in Pakistan
Martin Dow Marker Limited has 117 medicine presentations registered in Pakistan under 44 brands, covering 43 generic medicines. Most of its products are in Anti-infectives, Endocrine & metabolic and Cardiovascular. Its brands with the most registered strengths and packs are Empaphage-M (Empagliflozin + Metformin), Glucophage XR (Metformin), Klaribact (Clarithromycin) and Mercefex (Ceftriaxone). 117 products have an official DRAP price on MedInfoBase. See all 44 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer - Martin Dow Group
- Address
- Nice Trade Orbit Building, Plot No. 44-A & B, PECHS Block VI, Shahrah-e-Faisal, Karachi, Pakistan
- Website
- martindowmarker.com ↗
- Phone
- +92 21 111 111 634
- info@martindow.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Martin Dow Marker Limited is priced against the market
103 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Ranulcid | Gentamicin | 50 mg/2 mL | Injection | 5x2ml | 025487 | PKR 142.43 | PKR 14.24/mL | No comparator |
| Refobacin | Gentamicin | 40 mg/2 mL | Injection | 5x2ml | 006472 | PKR 196.14 | PKR 19.61/mL | 🔒 Pharma Pro |
| Refobacin | Gentamicin | 80 mg/2 mL | Injection | 5x2ml | 006473 | PKR 290.76 | PKR 29.08/mL | 🔒 Pharma Pro |
| Refobacin | Gentamicin | 5 mg/mL gentamicin sulfate (equiv. 3 mg/mL gentamicin; 0.3%) | Ophthalmic drops | 10 ml | 007567 | PKR 51.62 | PKR 5.16/mL | No comparator |
| Refobacin | Gentamicin | 10 mg/mL | Injection | 5x1ml | 014785 | PKR 74.80 | PKR 14.96/mL | No comparator |
| Refobacin | Gentamicin | 20 mg/mL | Injection | 5x1ml | 023375 | PKR 122.99 | PKR 24.60/mL | 🔒 Pharma Pro |
All 44 Martin Dow Marker brands in Pakistan
- Actilyse Alteplase · 50 mg infusion
- Advaxaban Apixaban · 2.5 mg tablet, 5 mg tablet
- Advit D Cholecalciferol · 5 mg injection
- Anglozar Losartan · 100 mg tablet, 25 mg tablet, 50 mg tablet
- Anglozar-D Losartan + Hydrochlorothiazide · 100 mg + 100 mg tablet, 100 mg + 12.5 mg tablet, 100 mg + 25 mg tablet
- Arzomic Azithromycin · 200 mg/5 mL suspension, 250 mg tablet, 500 mg tablet
- Bi Haler Budesonide + Formoterol · 200 mcg + 200 mcg inhalation, 400 mcg + 400 mcg inhalation
- Buscopan Hyoscine butylbromide · 20 mg/mL injection
- Cefomerc Cefotaxime · 1 g injection, 250 mg injection, 500 mg injection
- Concor Bisoprolol fumarate · 10 mg tablet, 2.5 mg tablet, 5 mg tablet
- Depex Fluoxetine · 20 mg capsule
- Dormicum Midazolam · 5 mg/5 mL injection
- Empaphage Empagliflozin · 10 mg tablet, 25 mg tablet
- Empaphage-M Empagliflozin + Metformin · 10 mg + 1000 mg tablet, 12.5 mg + 1000 mg tablet, 12.5 mg + 500 mg tablet
- Exigentin Loratadine · 10 mg tablet, 5 mg/5 mL syrup
- Glucophage Metformin · 1 g tablet, 250 mg tablet, 500 mg tablet
- Glucophage XR Metformin · 1000 mg tablet, 500 mg tablet, 750 mg tablet
- Ibusoft Ibuprofen · 100 mg/5 mL suspension, 200 mg capsule, 400 mg capsule
- Klaribact Clarithromycin · 125 mg/5 mL suspension, 125 mg/5 mL drops, 250 mg tablet
- Laxocare Lactulose · 3.35 mg/5 mL syrup
- Levomerc Levofloxacin · 250 mg tablet, 500 mg tablet
- Lodopin Amlodipine · 10 mg tablet, 2.5 mg tablet, 5 mg tablet
- Lodoz Bisoprolol + Hydrochlorothiazide · 2.5 mg + 6.25 mg tablet
- Lumairia Artemether + Lumefantrine · 20 mg + 120 mg tablet, 40 mg + 240 mg tablet
- Mercefex Ceftriaxone · 1 g injection, 250 mg injection, 500 mg injection
- Mercip Ciprofloxacin · 250 mg tablet, 500 mg tablet, 750 mg tablet
- Meropenex Meropenem · 1 g injection, 500 mg injection
- Merstatin Simvastatin · 10 mg tablet, 20 mg tablet
- Nespetro Moxifloxacin · 400 mg tablet
- Neurobion Thiamine + Pyridoxine + Cyanocobalamin, Thiamine (Vitamin B1) + Pyridoxine (Vitamin B6) + Cyanocobalamin (Vitamin B12) · 100 mg + 100 mg + 200 mcg tablet
- Nidonil Gliclazide · 80 mg tablet
- Omelcid Omeprazole · 20 mg capsule
- Ovi-f Clomifene citrate · 50 mg tablet
- Pailet Clopidogrel · 75 mg tablet
- Psyper Risperidone · 1 mg tablet, 2 mg tablet, 3 mg tablet
- Ranulcid Ranitidine, Gentamicin · 150 mg tablet, 300 mg tablet, 50 mg/2 mL injection
- Refobacin Gentamicin · 10 mg/mL injection, 20 mg/mL injection, 40 mg/2 mL injection
- Supramycin Doxycycline · 100 mg capsule
- Teril Carbamazepine · 200 mg tablet
- Tio Haler DPI Tiotropium · 18 mcg capsule
- Tixomer Cefixime · 400 mg capsule
- Tixomer Dry Cefixime · 100 mg/5 mL suspension, 200 mg/5 mL suspension
- Valium Diazepam · 10 mg/2 mL injection
- Vicet Levetiracetam · 250 mg tablet, 500 mg tablet
Martin Dow Marker: common questions
How many products does Martin Dow Marker have in Pakistan?
Martin Dow Marker Limited has 117 registered medicine presentations in Pakistan, sold under 44 brands and covering 43 generic medicines.
What are the main brands of Martin Dow Marker?
By number of registered strengths and packs, its largest brands are Empaphage-M (Empagliflozin + Metformin), Glucophage XR (Metformin), Klaribact (Clarithromycin), Mercefex (Ceftriaxone) and Refobacin (Gentamicin). This is not a sales ranking.
Which therapy areas does Martin Dow Marker cover?
The most products are in Anti-infectives (37), Endocrine & metabolic (31), Cardiovascular (16), CNS & mental health (10) and Gastrointestinal & hepatology (6).
Where can I see Martin Dow Marker medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.